These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21557768)

  • 1. Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test.
    Park GJ; Wiseman E; George J; Katelaris PH; Seow F; Fung C; Ngu MC
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1411-6. PubMed ID: 21557768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 13C-caffeine breath test detects significant fibrosis in patients with nonalcoholic steatohepatitis.
    Schmilovitz-Weiss H; Niv Y; Pappo O; Halpern M; Sulkes J; Braun M; Barak N; Rotman Y; Cohen M; Waked A; Tur-Kaspa R; Ben-Ari Z
    J Clin Gastroenterol; 2008 Apr; 42(4):408-12. PubMed ID: 18277896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
    Adams LA; George J; Bugianesi E; Rossi E; De Boer WB; van der Poorten D; Ching HL; Bulsara M; Jeffrey GP
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1536-43. PubMed ID: 21950746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C.
    Dinesen L; Caspary WF; Chapman RW; Dietrich CF; Sarrazin C; Braden B
    Dig Liver Dis; 2008 Sep; 40(9):743-8. PubMed ID: 18339592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD.
    Savvidou S; Hytiroglou P; Orfanou-Koumerkeridou H; Panderis A; Frantzoulis P; Goulis J
    J Clin Gastroenterol; 2009 Sep; 43(8):765-72. PubMed ID: 19525862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of ¹³C-methacetin breath test for the non-invasive evaluation of nonalcoholic fatty liver disease.
    Fierbinteanu-Braticevici C; Plesca DA; Tribus L; Panaitescu E; Braticevici B
    J Gastrointestin Liver Dis; 2013 Jun; 22(2):149-56. PubMed ID: 23799213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk.
    Tahan V; Canbakan B; Balci H; Dane F; Akin H; Can G; Hatemi I; Olgac V; Sonsuz A; Ozbay G; Yurdakul I; Senturk H
    Hepatogastroenterology; 2008; 55(85):1433-8. PubMed ID: 18795706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function.
    Park GJ; Katelaris PH; Jones DB; Seow F; Le Couteur DG; Ngu MC
    Hepatology; 2003 Nov; 38(5):1227-36. PubMed ID: 14578861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.
    Kaneda H; Hashimoto E; Yatsuji S; Tokushige K; Shiratori K
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1459-65. PubMed ID: 16911693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.
    Suzuki A; Angulo P; Lymp J; Li D; Satomura S; Lindor K
    Liver Int; 2005 Aug; 25(4):779-86. PubMed ID: 15998429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy.
    Park GJ; Katelaris PH; Jones DB; Seow F; Lin BP; Le Couteur DG; Ngu MC
    Aliment Pharmacol Ther; 2005 Sep; 22(5):395-403. PubMed ID: 16128677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
    Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
    Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Fierbinteanu-Braticevici C; Baicus C; Tribus L; Papacocea R
    J Gastrointestin Liver Dis; 2011 Jun; 20(2):153-9. PubMed ID: 21725512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation.
    Toniutto P; Fabris C; Bitetto D; Falleti E; Avellini C; Rossi E; Smirne C; Minisini R; Pirisi M
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1904-8. PubMed ID: 17914968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibro-α score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients.
    Omran MM; Farid K; Emran TM; Attallah AA
    Arab J Gastroenterol; 2011 Jun; 12(2):74-9. PubMed ID: 21684477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis.
    Tsang SW; Ng WF; Wu BP; Chow DA; Li ET; Wong TC
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):116-21. PubMed ID: 16706822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
    Bugianesi E; Marchesini G; Gentilcore E; Cua IH; Vanni E; Rizzetto M; George J
    Hepatology; 2006 Dec; 44(6):1648-55. PubMed ID: 17133473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).
    Yoneda M; Yoneda M; Mawatari H; Fujita K; Endo H; Iida H; Nozaki Y; Yonemitsu K; Higurashi T; Takahashi H; Kobayashi N; Kirikoshi H; Abe Y; Inamori M; Kubota K; Saito S; Tamano M; Hiraishi H; Maeyama S; Yamaguchi N; Togo S; Nakajima A
    Dig Liver Dis; 2008 May; 40(5):371-8. PubMed ID: 18083083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.